Osteoporosis: Non-hormonal treatment

Climacteric

Volumn 10, Issue SUPPL. 2, 2007, Pages 74-78

  Rizzoli, R ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Antiresorptive agents; Bisphosphonates; Bone formation stimulating agents; Denosumab; Non hormonal treatment; Osteoporosis; Strontium ranelate

Indexed keywords

ALENDRONIC ACID; CALCITONIN; CALCIUM; DENOSUMAB; IBANDRONIC ACID; PARATHYROID HORMONE; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; CONFERENCE PAPER; DOSE RESPONSE; DRUG INHIBITION; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; VERTEBRA FRACTURE;

ALENDRONATE; ANTIBODIES, MONOCLONAL; BONE DENSITY CONSERVATION AGENTS; CALCITONIN; CALCIUM, DIETARY; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; ETIDRONIC ACID; FEMALE; FRACTURES, BONE; HUMANS; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; RALOXIFENE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIOPHENES; VITAMIN D; WOMEN'S HEALTH;

EID: 34548841961     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130701600815     Document Type: Conference Paper

References (23)

1. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99
2. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927-38
3. Roux C, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 2004;20:433-9
4. Chesnut IC, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9
5. Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the Mobile Study. Ann Rheum Dis 2006;65:654-61
6. Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the Dosing Intravenous Administration Study. Arthritis Rheum 2006;54:1838-46
7. Solomon DH, Brookhart MA, Gandhi TK, et al. Adherence with osteoporosis practice guidelines: a multilevel analysis of patient, physician, and practice setting characteristics. Am J Med 2004;117:919-24
8. Rosen CJ, Hochberg MC, Bonnick SL, et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 2005;20:141-51
9. Silverman SL, Watts NB, Delmas PD, Lange JL, Lindsay R. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The Risedronate And Alendronate (REAL) cohort study. Osteoporos Int 2007;18:25-34
10. Boonen S, McClung MR, Eastell R, El-Hajj Fuleihan G, Barton IP, Delmas P. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc 2004;52:1832-9
11. Boonen S, Laan RF, Barton IP, Watts NB. Effect of osteoporosis treatments on risk of nonvertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int 2005;16:1291-8
12. Delmas PD, Genant HK, Crans GG, et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 2003;33:522-32
13. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of vitamin D on falls: a meta-analysis. JAMA 2004;291:1999-2006
14. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005;293:2257-64
15. Grant AM, Avenell A, Campbell MK, et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or Vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 2005;365:1621-8
16. Jackson RD, Lacroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006;354:669-83
17. Boonen S, Vanderschueren A, Haetjens P, Lips P. Evidence for hip fracture risk reduction with calcium and vitamin D from a comparative meta-analysis of randomized controlled trials. J Bone Miner Res 2006;21:S60
18. Silverman SL, Mathisen A, Gallwitz W. Effect of parathyroid hormone (1-84) in reducing new vertebral fractures regardless of baseline vertebral fracture status in patients with a wide range of clinical risk factors. J Bone Miner Res 2006;21:S173
19. Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005;353:555-65
20. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68
21. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment Of Peripheral Osteoporosis (TROPOS) Study. J Clin Endocrinol Metab 2005;90:2816-22
22. Reginster JY, Roux C, Compston J, Ortolani S. Strontium ranelate: an anti-osteoporotic treatment demonstrated vertebral and nonvertebral anti-fracture efficacy over 5 years in postmenopausal osteoporotic women. Osteoporos Int 2006;17:S14
23. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354:821-31